13.26
1.77%
0.23
アフターアワーズ:
13.25
-0.010
-0.08%
Cidara Therapeutics Inc (CDTX) 最新ニュース
Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire
How Cidara Got Its Molecule Back - BioProcess Online
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire
(CDTX) Investment Analysis and Advice - Stock Traders Daily
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com
(CDTX) On The My Stocks Page - Stock Traders Daily
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology
Cidara Therapeutics Announces Two Presentations on - GlobeNewswire
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan
How to Take Advantage of moves in (CDTX) - Stock Traders Daily
Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations
Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada
Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World
Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch
Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com
Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan
Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance
Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
XTX Topco Ltd Purchases Shares of 8,284 Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics expands Scientific Advisory Board - Investing.com
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts - GlobeNewswire
Acute Vulvovaginal Candidiasis Treatment Market Size, Share, Growth and Industry Trends - meramandsaur.in
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches - Fierce Biotech
IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Decrease in Short Interest - MarketBeat
Codexis Inc. (CDXS) Stock: A Year of Declines and Increases - The InvestChronicle
The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News
Capricor Therapeutics Shares Rise After Deramiocel Deal With Nippon Shinyaku - MarketWatch
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
HC Wainwright Reaffirms "Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX) - MarketBeat
Cognizant Technology Solutions (NASDAQ:CTSH) Stock Rating Upgraded by StockNews.com - Defense World
Cidara therapeutics chief scientific officer sells shares worth over $10k - Investing.com India
Cidara Therapeutics (NASDAQ:CDTX) Upgraded to "Hold" at StockNews.com - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells $10,755.36 in Stock - MarketBeat
Cidara Therapeutics executive sells over $10k in company stock - Investing.com
(CDTX) Trading Advice - Stock Traders Daily
Cidara Therapeutics announces workforce cut to focus on flu drug - Investing.com India
Cidara Therapeutics announces workforce cut to focus on flu drug By Investing.com - Investing.com Australia
Cidara axes 30% of staff to focus on flu prevention drug - Pharmaceutical Technology
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Cidara Therapeutics announces workforce reduction and trial focus By Investing.com - Investing.com Canada
大文字化:
|
ボリューム (24 時間):